COST-EFFECTIVENESS OF TOFACTINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER CONVENTIONAL THERAPY IN SPAIN

被引：0
|
作者：
Taxonera, C. [1 ]
de Andres-Nogales, F. [2 ]
Garcia, S. [3 ]
Sanchez-Guerrero, A. [4 ]
Menchen, B. [4 ]
Peral, C. [5 ]
Cabez, A. [5 ]
Gomez, S. [5 ]
Lopez, A. [6 ]
Casado, M. A. [2 ]
Menchen, L. [7 ]
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] PORIB, Pozuelo De Alarcon M, Spain
[3] Hosp Univ Miguel Servet, Zaragoza, Spain
[4] Hosp Univ Puerta de Hierro Majadahonda, Madrid, Spain
[5] Pfizer SLU, Madrid, Spain
[6] Pfizer SLU, Madrid M, Spain
[7] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI17
引用
收藏
页码：S619 / S619
页数：1
相关论文
共 50 条
  • [21] The efficacy of initial treatment with infliximab without previous conventional therapy in patients with moderate-to-severe ulcerative colitis
    Prymak, O.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S280 - S280
  • [22] COST-EFFECTIVENESS ANALYSIS OF BIOSIMILARS BASED TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE CROHN DISEASE IN SPAIN
    Fernandez Santos, J. M.
    Monte Boquet, E.
    Borras Blasco, J.
    Romero de la Cruz, E.
    Gonzalez Galan, R.
    Singh, M. K.
    Sharma, V
    Merino-Bohorquez, V
    VALUE IN HEALTH, 2022, 25 (07) : S362 - S362
  • [23] Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
    Schlueter, Max
    Finn, Elaine
    Diaz, Silvia
    Dilla, Tatiana
    Inciarte-Mundo, Jose
    Fakhouri, Walid
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 395 - 403
  • [24] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [25] An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis
    Johnson, Amanda M.
    Loftus Jr, Edward V.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (12) : 1317 - 1327
  • [26] Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan
    Kobayashi, Taku
    Hoshi, Masato
    Yuasa, Akira
    Arai, Shoko
    Ikeda, Mitsunobu
    Matsuda, Hiroyuki
    Kim, Seok-Won
    Hibi, Toshifumi
    PHARMACOECONOMICS, 2023, 41 (05) : 589 - 604
  • [27] Cost-effectiveness analysis of infliximab versus CinnoRA in the treatment of moderate to severe ulcerative colitis in Iranian patients
    Olfatifar, Meysam
    Aghdaei, Hamid Asadzadeh
    Dehkordi, Ayda Hasanpour
    Shahrokh, Shabnam
    Pourhoseingholi, Mohamad Amin
    Balaii, Hedieh
    Rajabnia, Mohsen
    Ivanchuk, Maria
    Ivanchuk, Pavlo
    Nazari, Saeed Hashemi
    Sabour, Siamak
    Rohani, Pejman
    Mehralian, Gholamhossein
    Khodakarim, Soheila
    Hatami, Behzad
    Malekpour, Habib
    Sherkat, Ghazal
    Zali, Mohammad Reza
    Pordanjani, Sajjad Rahimi
    IMMUNOPATHOLOGIA PERSA, 2023, 9 (02):
  • [28] A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis
    Tsai, H. H.
    Punekar, Y. S.
    Morris, J.
    Fortun, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (10) : 1230 - 1239
  • [29] Cost-effectiveness of tacrolimus for the treatment of moderate-to-severe lupus nephritis in China
    Kim, Soyoung
    Ooi, Adrian Yit Reen
    Stephens, Thomas
    Jiang, Hongsi
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (13) : 1125 - 1141
  • [30] Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
    Jia, Xiaoying
    Zhao, Yang
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Mendelsohn, Alan M.
    Lowry, Simon
    Feldman, Steve
    Wu, Jashin J.
    Armstrong, April W.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 740 - 748
12345